Karyopharm Therapeutics and Antengene Corporation announced their entry into an exclusive license agreement for the development and commercialization of four of Karyopharm's novel, oral drug candidates, including selinexor, Karyopharm's lead SINE compound, eltanexor, Karyopharm's second-generation SINE compound, verdinexor, Karyopharm's lead compound in development for viral and other non-oncology indications, and KPT-9274, Karyopharm's dual inhibitor of PAK4
demonstrated that PPAR[gamma] is involved in radiation-induced epithelial-to-mesenchymal transition (EMT) in glioma by interacting with p21-activated kinase 4 (PAK4
), resulting in increased Nox1 expression and reactive oxygen species (ROS) .
Banasavadi-Siddegowda et al., "A novel interaction of PAK4
with PPARy to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma," Oncogene, vol.
SH3RF2 functions as an oncogene by mediating PAK4
These are the EphA2 null mouse  and PAK4
null mouse .
Ryu et al., "Repositioning potential of pak4
to osteoclastic bone resorption," Journal of Bone and Mineral Research, vol.
In the postinfarct heart, miR-24 enhances survival, proliferation, and angiogenic function of EC by targeting GATA2, p21-activated kinase PAK4
, and eNOS.
Inhibition of endothelial miR-24 significantly reduced myocardial infarct size via prevention of endothelial apoptosis and enhancement of vascularity after AMI through targeting of the endothelium-enriched transcription factor GATA2 and the p21-activated kinase 4 (PAK4
), which led to preserved cardiac function and was closely related to HF .
confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/Erk-dependent pathways.
Here neurologists and other biomedical researchers explain in some detail how PAKs--particularly the oncogenic kinases PAK1 and PAK4
and their blockers--may control various aspects of life and health, and how mammalian PAKs have functionally evolved from their ancestral origins in unicellular organisms such as yeast and amoebas through a series of mutations over millions of years.
Se detectaron frecuentes mutaciones no descritas en la via de PI3K o en otras vias de kinasas, por ejemplo, en los tres genes que codifican los componentes de la va PI3K/Akt (PDK1, AKT2 y kinasa activada por p21 (PAK4
)) en cancer colorrectal.